Matins Pharma

Matins Pharma is a clinical-stage biopharmaceutical company dedicated to developing transformative treatments for metabolic disorders, with a primary focus on Type 2 diabetes and non-alcoholic steatohepatitis (NASH). The company's lead program, MT-3011, is a liver-selective glucokinase activator (GKA) that was originally discovered by Pfizer. By specifically targeting glucokinase in the liver, MT-3011 aims to lower blood glucose levels and reduce hepatic fat accumulation while avoiding the hypoglycemia and hypertriglyceridemia risks associated with systemic GKAs. Matins Pharma is currently advancing its clinical pipeline to address significant unmet needs in the global metabolic health market.